

**Remarks /Arguments**

Group I, which comprises the compounds of Formula I and Formula II and pharmaceutical compositions comprising these compounds, is elected for examination. Claims 1-41 read on Group I.


Groups II-X are directed to methods of using the claimed compounds and compositions in the treatment of various CCR2 mediated diseases. Claims 42-44, which are directed to Groups II-X of the restriction requirement, are withdrawn. Claims 42-44 should be rejoined once the chemical compound claims are allowed.

Paragraph 4 of the Restriction Requirement refers to the compounds listed in Claim 40 as "more than one species of the generic invention" and states that they also are lacking in unity of invention. It wasn't explicitly stated whether an election of a species was required. If an election of species is required, applicants elect the compound of Example 2 on page 56.

This is believed to be a complete response to the Restriction Requirement. If the Examiner wishes to discuss any matter with respect to this response, she is invited to telephone the undersigned attorney.

As this response is timely filed, no fee is due. If a fee associated with this Response is required, it may be charged to Merck Deposit Account No.13-2755.

Respectfully submitted,

By 

James L. McGinnis

Reg. No. 34,387

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0641

Date: March 4, 2009